Indoline 5-HT2A Agonists With Reduced Hallucinogenic Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new non-hallucinogenic 5-HT2A agonist molecules to treat mental illnesses and neurological disorders, as existing psychedelics have significant side effects such as hallucinations, limiting their use outside clinical settings.
Innovation Solution
Development of indoline compounds that modulate serotonin receptor subtypes, particularly 5-HT2A, through direct binding to these receptors, offering a therapeutic approach for mental illnesses and neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classic psychedelics (mescaline, DMT, psilocybin, LSD) are used to treat neuropsychiatric diseases, then therapeutic effectiveness is improved through 5-HT2A receptor activation, but hallucinogenic side effects worsen and limit use outside clinical settings
Solution Approach 1:
The patent modifies molecular parameters of psychedelic compounds by replacing the indole nitrogen with a CH group to create indoline derivatives, and by introducing specific substituents at defined positions. These structural parameter changes result in compounds that maintain 5-HT2A receptor affinity while reducing hallucinogenic effects, thereby resolving the contradiction between therapeutic effectiveness and side effect profile
Solution Approach 2:
The patent introduces specific local modifications to the molecular structure, including substituents at R1, R2, R2′, R2′′, R3, R4, R5, and R6 positions. These localized structural changes allow the compound to selectively activate 5-HT2A receptors with different binding characteristics compared to classic psychedelics, achieving therapeutic effects with reduced hallucinogenic properties
2Object-affected harmful factors
If non-hallucinogenic 5-HT2A agonist analogs are developed, then hallucinogenic side effects are reduced, but therapeutic development remains in its infancy and effectiveness is unproven
Solution Approach 1:
The patent employs a systematic structure-activity relationship (SAR) approach where compounds are designed, synthesized, and tested to gather feedback on their pharmacological properties. This iterative process allows optimization of the indoline derivatives to achieve the desired balance between 5-HT2A agonism and reduced hallucinogenic effects, moving non-hallucinogenic analogs from early development toward proven therapeutic agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The indoline compounds provide a non-hallucinogenic treatment option for mental illnesses and neurological disorders by effectively activating serotonin receptors, potentially reducing side effects and enhancing therapeutic outcomes.
Implementation Method 1
Compounds of the present application modulate the activity of serotonin receptor subtypes, in particular 5-HT2A, by direct binding to these receptors
Data Source
AI summary
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptors in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses and CNS disorders and/or associated endophenotypes and/or symptom clusters. Wherein Q is selected from (Q1), (Q2), (Q2′), (Q4) and (Q5).